NasdaqGS - Delayed Quote USD

Nanobiotix S.A. (NBTX)

3.3500
+0.0400
+(1.21%)
At close: May 8 at 4:00:00 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
-11,609
-11,609
30,058
0
10
Operating Expense
56,782
56,782
56,836
46,703
52,588
Operating Income
-68,391
-68,391
-26,778
-46,703
-52,578
Net Non Operating Interest Income Expense
-2,625
-2,625
-6,480
-12,436
-658
Other Income Expense
2,985
2,985
-6,322
2,106
6,238
Pretax Income
-68,031
-68,031
-39,580
-57,033
-46,998
Tax Provision
101
101
120
10
5
Net Income Common Stockholders
-68,132
-68,132
-39,700
-57,041
-47,003
Diluted NI Available to Com Stockholders
-68,132
-68,132
-39,700
-57,041
-47,003
Basic EPS
-1.44
-1.44
-1.08
-1.64
-1.35
Diluted EPS
-1.44
-1.44
-1.08
-1.64
-1.35
Basic Average Shares
47,265.1890
47,265.1890
36,759.2590
34,781.0980
34,733.4180
Diluted Average Shares
47,265.1890
47,265.1890
36,759.2590
34,781.0980
34,733.4180
Total Operating Income as Reported
-68,392
-68,392
-26,779
-46,702
-52,579
Rent Expense Supplemental
--
--
--
--
9,638
Total Expenses
56,782
56,782
56,836
46,703
52,588
Net Income from Continuing & Discontinued Operation
-68,132
-68,132
-39,700
-57,041
-47,003
Normalized Income
-70,370.7500
-70,370.7500
-34,958.5000
-59,147
-51,587.9300
Interest Income
2,629
2,629
1,217
256
0
Interest Expense
8,086
8,086
7,982
5,837
671
Net Interest Income
-2,625
-2,625
-6,480
-12,436
-658
EBIT
-59,945
-59,945
-31,598
-51,196
-46,327
EBITDA
-58,324
-58,324
-30,085
-49,696
-44,767
Reconciled Depreciation
1,621
1,621
1,513
1,500
1,560
Net Income from Continuing Operation Net Minority Interest
-68,132
-68,132
-39,700
-57,041
-47,003
Total Unusual Items Excluding Goodwill
2,985
2,985
-6,322
2,106
6,238
Total Unusual Items
2,985
2,985
-6,322
2,106
6,238
Normalized EBITDA
-61,309
-61,309
-23,763
-51,802
-51,005
Tax Rate for Calcs
0.0003
0.0003
0.0003
0
0.0003
Tax Effect of Unusual Items
746.2500
746.2500
-1,580.5000
0
1,653.0700
12/31/2021 - 12/11/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IPHA Innate Pharma S.A.
2.3800
0.00%
 
VYNE VYNE Therapeutics Inc.
1.3000
-5.11%
 
MEDCL.PA MedinCell S.A.
15.50
0.00%
 
GNFT Genfit S.A.
4.3000
+2.38%
 
ACTU Actuate Therapeutics, Inc. Common stock
9.90
+6.45%
 
SPRO Spero Therapeutics, Inc.
0.5750
-0.52%
 
CLLS Cellectis S.A.
1.5300
+2.00%
 
IVA Inventiva S.A.
3.5200
-1.12%
 
OKYO OKYO Pharma Limited
1.4800
+0.68%
 
ORGS Orgenesis Inc.
1.9000
-6.40%